MA38827A1 - Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives - Google Patents

Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives

Info

Publication number
MA38827A1
MA38827A1 MA38827A MA38827A MA38827A1 MA 38827 A1 MA38827 A1 MA 38827A1 MA 38827 A MA38827 A MA 38827A MA 38827 A MA38827 A MA 38827A MA 38827 A1 MA38827 A1 MA 38827A1
Authority
MA
Morocco
Prior art keywords
inhibitor
treatment
combination
hyperproliferative diseases
erk
Prior art date
Application number
MA38827A
Other languages
English (en)
Inventor
Marcia Belvin
John Moffat
Mark Merchant
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38827A1 publication Critical patent/MA38827A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des combinaisons comprenant un inhibiteur de mek (comme gdc-0973 ou gdc-0623) ou d'un sel pharmaceutiquement acceptable de celui-ci et d'un inhibiteur d'erk (comme gdc-0994). Les combinaisons sont particulièrement utiles pour traiter des troubles hyperprolifératifs, tels que le cancer.
MA38827A 2013-09-05 2014-09-04 Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives MA38827A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874206P 2013-09-05 2013-09-05
PCT/EP2014/068776 WO2015032840A1 (fr) 2013-09-05 2014-09-04 Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives

Publications (1)

Publication Number Publication Date
MA38827A1 true MA38827A1 (fr) 2017-10-31

Family

ID=51492945

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38827A MA38827A1 (fr) 2013-09-05 2014-09-04 Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives

Country Status (21)

Country Link
US (1) US9532987B2 (fr)
EP (1) EP3041471A1 (fr)
JP (2) JP2016531139A (fr)
KR (1) KR20160048807A (fr)
CN (1) CN105517548B (fr)
AR (1) AR097556A1 (fr)
AU (1) AU2014317119B2 (fr)
CA (1) CA2916619A1 (fr)
CL (1) CL2016000042A1 (fr)
EA (1) EA034872B1 (fr)
HK (1) HK1218072A1 (fr)
IL (1) IL243251B (fr)
MA (1) MA38827A1 (fr)
MX (1) MX370417B (fr)
PE (1) PE20160529A1 (fr)
PH (1) PH12016500270A1 (fr)
SG (1) SG11201600989VA (fr)
TW (1) TW201605477A (fr)
UA (1) UA120423C2 (fr)
WO (1) WO2015032840A1 (fr)
ZA (1) ZA201600091B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090220A1 (es) * 2012-03-01 2014-10-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
CR20160309A (es) 2013-12-06 2016-08-25 Genentech Inc Inhibidores de serina/treonina cinasa
MX2016008624A (es) * 2013-12-30 2017-01-06 Genentech Inc Inhibidores de serina/treonina cinasa.
WO2016162325A1 (fr) 2015-04-07 2016-10-13 Astrazeneca Ab Dérivés de 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-ones substitués utilisés comme inhibiteurs de kinase
WO2017080980A1 (fr) 2015-11-09 2017-05-18 Astrazeneca Ab Dérivés de dihydropyrrolopyrazinone utiles dans le traitement du cancer
SG11201803066VA (en) 2015-11-09 2018-05-30 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
CN105330643B (zh) 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
JP2019518426A (ja) * 2016-04-15 2019-07-04 ジェネンテック， インコーポレイテッド がんの診断及び治療方法
WO2018039211A1 (fr) * 2016-08-23 2018-03-01 Genentech, Inc. Polythérapies pour le traitement du cancer du pancréas
CN115025225A (zh) 2016-11-25 2022-09-09 基诺富公司 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
JP2019019094A (ja) * 2017-07-19 2019-02-07 学校法人福岡大学 変異ｋｒａｓ関連シグナル阻害用組成物
CA3073073A1 (fr) 2017-09-08 2019-03-14 F. Hoffmann-La Roche Ag Methodes diagnostiques et therapeutiques du cancer
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
WO2019158579A1 (fr) 2018-02-13 2019-08-22 Vib Vzw Ciblage d'une maladie résiduelle minimale dans le cancer avec des antagonistes de rxr
US20220265584A1 (en) * 2019-07-11 2022-08-25 Emory University Combination Therapies for Managing Cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE504565T1 (de) 2005-10-07 2011-04-15 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
US7893085B2 (en) 2006-08-21 2011-02-22 Genentech, Inc Aza-benzothiophenyl compounds and methods of use
MX2009001878A (es) 2006-08-21 2009-03-03 Genentech Inc Compuestos de aza-benzofuranilo y metodos de uso.
CL2007003444A1 (es) 2006-11-30 2008-06-27 Genentech Inc Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
JP5580735B2 (ja) 2007-06-12 2014-08-27 ジェネンテック， インコーポレイテッド Ｎ−置換アザインドール類及び使用方法
KR20100101666A (ko) 2007-12-19 2010-09-17 제넨테크, 인크. ８-아닐리노이미다조피리딘 및 항암제 및/또는 소염제로서의 이들의 용도
PE20091158A1 (es) 2007-12-19 2009-08-28 Genentech Inc 5-anilinoimidazopiridinas y metodos de uso
KR20100099185A (ko) 2007-12-21 2010-09-10 제넨테크, 인크. 아자인돌리진 및 이용 방법
MX2010014559A (es) 2008-07-01 2011-03-04 Genentech Inc Heterociclos bicíclicos sustituidos y metodos de uso.
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
SG178866A1 (en) 2009-08-24 2012-04-27 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
CA2776944A1 (fr) 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek
AU2011332043C1 (en) 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
EP2681215B1 (fr) 2011-02-28 2015-04-22 Array Biopharma, Inc. Inhibiteurs de sérine/thréonine kinase
WO2012145503A1 (fr) 2011-04-21 2012-10-26 Novartis Ag Combinaisons pharmaceutiques
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
AR090220A1 (es) 2012-03-01 2014-10-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP2854804B1 (fr) 2012-05-30 2019-11-20 F.Hoffmann-La Roche Ag Hétérocycles pyrrolidino
SG10201708494QA (en) 2012-08-17 2017-11-29 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
JP6378182B2 (ja) 2012-08-27 2018-08-22 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
CN104755478B (zh) 2012-10-16 2017-10-10 霍夫曼-拉罗奇有限公司 丝氨酸/苏氨酸激酶抑制剂
CR20160309A (es) 2013-12-06 2016-08-25 Genentech Inc Inhibidores de serina/treonina cinasa
BR112016015235A2 (pt) 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
MX2016008624A (es) 2013-12-30 2017-01-06 Genentech Inc Inhibidores de serina/treonina cinasa.
MY188526A (en) 2014-04-09 2021-12-18 Genentech Inc Process for the manufacturing of medicaments

Also Published As

Publication number Publication date
AU2014317119A1 (en) 2016-03-03
SG11201600989VA (en) 2016-03-30
ZA201600091B (en) 2017-04-26
CA2916619A1 (fr) 2015-03-12
HK1218072A1 (zh) 2017-02-03
UA120423C2 (uk) 2019-12-10
WO2015032840A1 (fr) 2015-03-12
PE20160529A1 (es) 2016-05-21
PH12016500270A1 (en) 2016-05-16
MX2016002857A (es) 2016-06-22
AR097556A1 (es) 2016-03-23
CN105517548B (zh) 2020-01-21
US9532987B2 (en) 2017-01-03
EA034872B1 (ru) 2020-03-31
EA201690513A1 (ru) 2016-07-29
MX370417B (es) 2019-12-10
JP2019031517A (ja) 2019-02-28
EP3041471A1 (fr) 2016-07-13
KR20160048807A (ko) 2016-05-04
AU2014317119B2 (en) 2019-12-05
CL2016000042A1 (es) 2016-08-05
IL243251B (en) 2019-02-28
US20150111869A1 (en) 2015-04-23
JP2016531139A (ja) 2016-10-06
CN105517548A (zh) 2016-04-20
TW201605477A (zh) 2016-02-16

Similar Documents

Publication Publication Date Title
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
MA41013B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MX2018010192A (es) Inhibidores de glucosidasa.
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA39984B1 (fr) Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
MX2014000518A (es) Inhibidores de la tirosina quinasa de bruton.
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MX2018010191A (es) Inhibidores de glucosidasa.
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
MA35661B1 (fr) Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire
BR112016018170A2 (pt) métodos para tratar doença de alzheimer
MX2018001737A (es) Mecanismo de resistencia a inhibidores de bromodominio bet.
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EP3702470A3 (fr) Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
WO2015126930A3 (fr) Pharmacothérapie à effet "booster" pour lutter contre les infections à mycobacterium
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA41809B1 (fr) Biotine pour le traitement de la sclérose latérale amyotrophique
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
MA42419B1 (fr) Méthode de traitement de l'encéphalopathie hépatique